Terms: = Thyroid cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Clinical Outcome
15 results:
1. Presumed Pathogenic Germ Line and Somatic Variants in African American thyroid cancer.
Hurst ZA; Liyanarachchi S; Brock P; He H; Nabhan F; Veloski C; Toland AE; Ringel MD; Jhiang SM
Thyroid; 2024 Mar; 34(3):378-387. PubMed ID: 38062767
[No Abstract] [Full Text] [Related]
2. Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies.
Naderi A
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1267. PubMed ID: 32706923
[TBL] [Abstract] [Full Text] [Related]
3. Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer.
Tesselaar MH; Smit JW; Nagarajah J; Netea-Maier RT; Plantinga TS
J Mol Endocrinol; 2017 Nov; 59(4):R141-R154. PubMed ID: 28931558
[TBL] [Abstract] [Full Text] [Related]
4. Application of molecular biology of differentiated thyroid cancer for clinical prognostication.
Marotta V; Sciammarella C; Colao A; Faggiano A
Endocr Relat Cancer; 2016 Nov; 23(11):R499-R515. PubMed ID: 27578827
[TBL] [Abstract] [Full Text] [Related]
5. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract] [Full Text] [Related]
6. A comparative study of cell cycle mediator protein expression patterns in anaplastic and papillary thyroid carcinoma.
Evans JJ; Crist HS; Durvesh S; Bruggeman RD; Goldenberg D
Cancer Biol Ther; 2012 Jul; 13(9):776-81. PubMed ID: 22688732
[TBL] [Abstract] [Full Text] [Related]
7. Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification.
Pulcrano M; Boukheris H; Talbot M; Caillou B; Dupuy C; Virion A; De Vathaire F; Schlumberger M
Thyroid; 2007 Jul; 17(7):639-46. PubMed ID: 17696834
[TBL] [Abstract] [Full Text] [Related]
8. The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression.
Ferru A; Fromont G; Gibelin H; Guilhot J; Savagner F; Tourani JM; Kraimps JL; Larsen CJ; Karayan-Tapon L
Br J Cancer; 2006 Dec; 95(12):1670-7. PubMed ID: 17117177
[TBL] [Abstract] [Full Text] [Related]
9. Diffuse sclerosing variant of papillary thyroid carcinoma: a clinicopathologic and immunophenotypic analysis of 22 cases.
Thompson LD; Wieneke JA; Heffess CS
Endocr Pathol; 2005; 16(4):331-48. PubMed ID: 16627920
[TBL] [Abstract] [Full Text] [Related]
10. Small-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases.
Soriano P; Navarro S; Gil M; Llombart-Bosch A
Virchows Arch; 2004 Sep; 445(3):292-7. PubMed ID: 15248064
[TBL] [Abstract] [Full Text] [Related]
11. Molecular genotyping of medullary thyroid carcinoma can predict tumor recurrence.
Sheikh HA; Tometsko M; Niehouse L; Aldeeb D; Swalsky P; Finkelstein S; Barnes EL; Hunt JL
Am J Surg Pathol; 2004 Jan; 28(1):101-6. PubMed ID: 14707871
[TBL] [Abstract] [Full Text] [Related]
12. Maspin in thyroid cancer: its relationship with p53 and clinical outcome.
Boltze C; Schneider-Stock R; Meyer F; Peters B; Quednow C; Hoang-Vu C; Roessner A
Oncol Rep; 2003; 10(6):1783-7. PubMed ID: 14534696
[TBL] [Abstract] [Full Text] [Related]
13. p53 mutations in thyroid carcinoma: tidings from an old foe.
Farid NR
J Endocrinol Invest; 2001; 24(7):536-45. PubMed ID: 11508790
[TBL] [Abstract] [Full Text] [Related]
14. thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations.
Shahedian B; Shi Y; Zou M; Farid NR
Mol Genet Metab; 2001 Feb; 72(2):155-63. PubMed ID: 11161841
[TBL] [Abstract] [Full Text] [Related]
15. Overexpression of p53 in tall cell variants of papillary thyroid carcinoma.
Rüter A; Dreifus J; Jones M; Nishiyama R; Lennquist S
Surgery; 1996 Dec; 120(6):1046-50. PubMed ID: 8957493
[TBL] [Abstract] [Full Text] [Related]
